These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 10886192)
1. Current status of antiangiogenic factors. Talks KL; Harris AL Br J Haematol; 2000 Jun; 109(3):477-89. PubMed ID: 10886192 [No Abstract] [Full Text] [Related]
2. Angiogenesis: a target for cancer therapy. Tortora G; Melisi D; Ciardiello F Curr Pharm Des; 2004; 10(1):11-26. PubMed ID: 14754402 [TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of novel antiangiogenic therapies. Scappaticci FA Expert Opin Investig Drugs; 2003 Jun; 12(6):923-32. PubMed ID: 12783597 [TBL] [Abstract][Full Text] [Related]
4. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Mazeron R; Anderson B; Supiot S; Paris F; Deutsch E Cancer Treat Rev; 2011 Oct; 37(6):476-86. PubMed ID: 21546163 [TBL] [Abstract][Full Text] [Related]
5. Cancer gene therapy targeting angiogenesis: an updated review. Liu CC; Shen Z; Kung HF; Lin MC World J Gastroenterol; 2006 Nov; 12(43):6941-8. PubMed ID: 17109514 [TBL] [Abstract][Full Text] [Related]
6. Natural compounds show antiangiogenic activity. Marwick C J Natl Cancer Inst; 2001 Nov; 93(22):1685. PubMed ID: 11717328 [No Abstract] [Full Text] [Related]
7. Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. Galbraith SM Br J Radiol; 2003; 76 Spec No 1():S83-6. PubMed ID: 15456717 [No Abstract] [Full Text] [Related]
8. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment. Gagne P; Akalu A; Brooks PC Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663 [TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic strategies and agents in clinical trials. Rosen L Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. Bocci G; Loupakis F Pharmacogenomics; 2011 Aug; 12(8):1077-80. PubMed ID: 21843059 [No Abstract] [Full Text] [Related]
12. Abstracts of the 1st European Conference on Tumor Angiogenesis and Antiangiogenic Therapy. Munich, Germany, 1-3 October 2004. Angiogenesis; 2004; 7 Suppl 1():1-53. PubMed ID: 15505925 [No Abstract] [Full Text] [Related]
13. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766 [TBL] [Abstract][Full Text] [Related]
14. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". Rak J; Yu JL Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893 [TBL] [Abstract][Full Text] [Related]
15. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Leach MO; Brindle KM; Evelhoch JL; Griffiths JR; Horsman MR; Jackson A; Jayson G; Judson IR; Knopp MV; Maxwell RJ; McIntyre D; Padhani AR; Price P; Rathbone R; Rustin G; Tofts PS; Tozer GM; Vennart W; Waterton JC; Williams SR; Workman P Br J Radiol; 2003; 76 Spec No 1():S87-91. PubMed ID: 15456718 [No Abstract] [Full Text] [Related]
16. Targeting angiogenesis with oral agents. Besse B; Armand JP; Soria JC Ann Oncol; 2006 Sep; 17 Suppl 10():x71-5. PubMed ID: 17018755 [No Abstract] [Full Text] [Related]
17. [Neoplasms and angiogenesis]. Lewy-Trenda I Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576 [TBL] [Abstract][Full Text] [Related]
18. Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer. Ebos JM; Quintela-Fandino M Curr Drug Targets; 2016; 17(15):1706. PubMed ID: 27109490 [No Abstract] [Full Text] [Related]
19. Thalidomide, an antiangiogenic agent with clinical activity in cancer. Ng SS; Brown M; Figg WD Biomed Pharmacother; 2002 Jun; 56(4):194-9. PubMed ID: 12109812 [TBL] [Abstract][Full Text] [Related]